Show simple item record

dc.contributor.authorTorres Bueno, Cristina
dc.contributor.authorSánchez Barba, Mercedes 
dc.contributor.authorMirón Canelo, José Antonio 
dc.contributor.authorGonzález Núñez, Verónica 
dc.date.accessioned2026-01-21T09:42:10Z
dc.date.available2026-01-21T09:42:10Z
dc.date.issued2024
dc.identifier.citationTorres-Bueno, C., Sanchez-Barba, M., Miron-Canelo, J.-A., & Gonzalez-Nunez, V. (2024). Evolution of Fentanyl Prescription Patterns and Administration Routes in Primary Care in Salamanca, Spain: A Comprehensive Analysis from 2011 to 2022. Healthcare (Switzerland), 12(16). https://doi.org/10.3390/HEALTHCARE12161619es_ES
dc.identifier.urihttp://hdl.handle.net/10366/169115
dc.description.abstract[EN] Background: The escalating use of opioids contributes to social, health, and economic crises. In Spain, a notable surge in the medical prescription of opioids in recent years has been observed. The aim of this work was to assess the consumption rate of fentanyl, categorised by the different administration routes, in Primary Care in the province of Salamanca (Spain) spanning the years 2011 to 2022, and to compare it with the national trend and with data from the US. (2) Methods: Doses per inhabitant per day (DHD) were calculated, and interannual variations, as well as consumption rates, were subject to thorough analysis. (3) Results: The prevalence of fentanyl use in Salamanca has doubled from 1.21 DHD in 2011 to 2.56 DHD in 2022, with the transdermal system (TD) as the predominant administration route. This upward trajectory mirrors the national trend, yet the rise in fentanyl use is markedly lower than the reported data in the US. This finding may be attributed to an ageing population and potentially inappropriate fentanyl prescriptions, i.e., for the management of chronic non-cancer pain and other off-label prescriptions. (4) Conclusions: The use of fentanyl in Salamanca, particularly through transdermal systems, doubled from 2011 to 2022, aligning with the national trend. Preventive measures are imperative to prevent fentanyl misuse and moderate the observed escalation in consumption rates.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectOpioidses_ES
dc.subjectFentanyles_ES
dc.subjectConsumptiones_ES
dc.subjectDHDes_ES
dc.subjectTransdermal routees_ES
dc.subject.meshFentanyl *
dc.subject.meshDrug Users *
dc.subject.meshOff-Label Use *
dc.titleEvolution of fentanyl prescription patterns and administration routes in primary care in Salamanca, Spain: A comprehensive analysis from 2011 to 2022es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/healthcare12161619es_ES
dc.identifier.doi10.3390/HEALTHCARE12161619
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn2227-9032
dc.journal.titleHealthcarees_ES
dc.volume.number12es_ES
dc.issue.number16es_ES
dc.page.initial1619es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsfentanilo *
dc.subject.decsconsumidores de drogas *
dc.subject.decsprescripción en indicaciones no aprobadas *


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution  4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution 4.0 Internacional